Published in Lancet Oncol on May 01, 2005
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata | NCT00941889
Evaluation of Long Term Immunity Following HPV Vaccination | NCT02276521
Acceptance of Human Papillomavirus Vaccination in Postpartum Women (HPV Acceptance) | NCT00730704
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ (2007) 3.77
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol (2006) 3.34
Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis (2007) 2.93
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol (2005) 2.72
Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci (2006) 2.56
Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med (2008) 2.50
Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol (2009) 2.46
Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol (2010) 2.42
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis (2011) 2.19
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med (2006) 2.10
Papanicolaou screening behavior in mothers and human papillomavirus vaccine uptake in adolescent girls. Am J Public Health (2009) 2.03
Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc (2009) 1.96
Public awareness that HPV is a risk factor for cervical cancer. Br J Cancer (2007) 1.95
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 1.91
Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis (2010) 1.85
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine (2008) 1.75
Simultaneous amplification and identification of 25 human papillomavirus types with Templex technology. J Clin Microbiol (2006) 1.75
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin (2011) 1.73
Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ (2007) 1.72
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer (2010) 1.69
Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol (2007) 1.64
Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer (2006) 1.57
Human papillomavirus and HPV vaccines: a review. Bull World Health Organ (2007) 1.55
Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine (2010) 1.53
Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control (2009) 1.52
Applications of viral nanoparticles in medicine. Curr Opin Biotechnol (2011) 1.49
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin (2011) 1.46
Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol (2009) 1.45
A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. BMC Public Health (2007) 1.44
Cervical cancer, human papillomavirus, and vaccination. BMJ (2005) 1.43
Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol (2009) 1.35
Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis (2009) 1.35
Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis (2008) 1.35
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis (2009) 1.35
Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol (2006) 1.33
A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol (2011) 1.32
HPV knowledge, attitudes, and cultural beliefs among Hispanic men and women living on the Texas-Mexico border. Ethn Health (2009) 1.32
Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.31
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Dtsch Arztebl Int (2014) 1.26
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
Vaccine delivery using nanoparticles. Front Cell Infect Microbiol (2013) 1.24
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
An armamentarium of wart treatments. Clin Med Res (2006) 1.23
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol (2006) 1.20
Nanoparticle delivery systems in cancer vaccines. Pharm Res (2010) 1.20
Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol (2009) 1.20
How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med (2006) 1.20
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Plant-derived virus-like particles as vaccines. Hum Vaccin Immunother (2012) 1.18
Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study. J Womens Health (Larchmt) (2012) 1.17
HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol (2006) 1.15
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc (2008) 1.14
Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. Br Dent J (2015) 1.13
Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health (2015) 1.13
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study. BMC Public Health (2010) 1.11
The quality of life of patients with genital warts: a qualitative study. BMC Public Health (2010) 1.09
Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol (2006) 1.08
Enrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa. BMC Med Ethics (2007) 1.08
Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology (2007) 1.07
Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination. Cancer Causes Control (2009) 1.07
Effective strategies for HPV vaccine delivery: the views of pediatricians. J Adolesc Health (2007) 1.07
VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One (2012) 1.07
Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis (2013) 1.05
Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. J Clin Virol (2009) 1.05
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine (2010) 1.05
Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol (2009) 1.03
Multiple human papillomavirus infections and type competition in men. J Infect Dis (2011) 1.02
Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J (2011) 1.02
Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev (2010) 1.02
Characterization and experimental transmission of an oncogenic papillomavirus in female macaques. J Virol (2007) 1.02
Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res (2006) 1.02
The moral justification for a compulsory human papillomavirus vaccination program. Am J Public Health (2009) 1.02
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma. Infect Agent Cancer (2008) 1.00
Knowledge of HPV among United States Hispanic women: opportunities and challenges for cancer prevention. J Health Commun (2010) 1.00
Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J Clin Microbiol (2009) 1.00
Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycle. J Infect Dis (2009) 1.00
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol (2011) 0.99
Ensuring access to HPV vaccines through integrated services: a reproductive health perspective. Bull World Health Organ (2007) 0.98
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol (2010) 0.98
Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine (2012) 0.98
Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. Virology (2009) 0.98
Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med (2015) 0.98
A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study. PLoS One (2013) 0.97
Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence. Sex Health (2010) 0.97
Perceived need of a parental decision aid for the HPV vaccine: content and format preferences. Health Promot Pract (2011) 0.97
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 6.20
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med (2015) 5.86
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis (2006) 4.67
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol (2011) 3.66
The epidemiology of human papillomavirus infections. J Clin Virol (2005) 3.63
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet (2013) 3.25
The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis (2012) 3.19
Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19
Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis (2004) 3.18
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med (2008) 2.98
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol (2004) 2.95